



an Open Access Journal by MDPI

## Glycine-(and D-Serine)-Related Neurotransmission: Promising Therapeutic Targets with Still Unsolved Problems

Guest Editor:

### Dr. Luca Raiteri

Department of Pharmacy,  
Pharmacology and Toxicology  
Section, University of Genoa, Italy  
Viale Cembrano 4, 16148 Genoa,  
Italy

Deadline for manuscript  
submissions:

**30 June 2024**

### Message from the Guest Editor

The neurotransmitter glycine is involved in several physiological and pathological conditions in the Central Nervous System. This peculiar transmitter exhibits crucial inhibitory but also “excitatory” functions, the latter as a co-agonist of glutamate at the NMDA receptors.

In this Special Issue, it is hoped that original research as well as review articles will help to increase and disseminate knowledge in the field. Finally, studies leading to advances in the basic knowledge of the above-mentioned biological systems are undoubtedly important and their submission is encouraged.

Potential topics include (but are not limited to):

- Drugs interacting with glycine receptors or transporters and psychiatric disorders (schizophrenia, mood disorders, obsessive-compulsive disorder, addiction, cognitive disorders, etc.).
- D-serine and related pathological and pharmacological issues.
- Glycine/D-serine and pathological pain.
- Glycine/D-serine and neurodegenerative diseases, epilepsy, and startle syndromes, among others.
- Neurobiology of glycine-related neurotransmission, including interactions with other transmitters.



[mdpi.com/si/140383](https://mdpi.com/si/140383)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)